Literature DB >> 21709147

Special article: Future directions in malignant hyperthermia research and patient care.

Sharon J Hirshey Dirksen1, Marilyn Green Larach, Henry Rosenberg, Barbara W Brandom, Jerome Parness, Robert Scott Lang, Meera Gangadharan, Tyler Pezalski.   

Abstract

Malignant hyperthermia (MH) is a complex pharmacogenetic disorder of muscle metabolism. To more closely examine the complexities of MH and other related muscle disorders, the Malignant Hyperthermia Association of the United States (MHAUS) recently sponsored a scientific conference at which an interdisciplinary group of experts gathered to share new information and ideas. In this Special Article, we highlight key concepts and theories presented at the conference along with exciting new trends and challenges in MH research and patient care.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21709147      PMCID： PMC3184381          DOI： 10.1213/ANE.0b013e318222af2e

Source DB:  PubMed          Journal:  Anesth Analg        ISSN： 0003-2999            Impact factor:   5.108


  74 in total

1.  Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor.

Authors:  Xiaoli Zhao; Noah Weisleder; Xuehai Han; Zui Pan; Jerome Parness; Marco Brotto; Jianjie Ma
Journal:  J Biol Chem       Date:  2006-08-31       Impact factor: 5.157

2.  Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors.

Authors:  B R Fruen; J R Mickelson; C F Louis
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

3.  Malignant hyperthermia: update on susceptibility testing.

Authors:  Ronald S Litman; Henry Rosenberg
Journal:  JAMA       Date:  2005-06-15       Impact factor: 56.272

4.  Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient.

Authors:  Jordan L Newmark; Maria Voelkel; Barbara W Brandom; John Wu
Journal:  Anesthesiology       Date:  2007-08       Impact factor: 7.892

5.  Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.

Authors:  Carlos A Ibarra M; Shiwen Wu; Kumiko Murayama; Narihiro Minami; Yasuko Ichihara; Hirosato Kikuchi; Satoru Noguchi; Yukiko K Hayashi; Ryoichi Ochiai; Ichizo Nishino
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

Review 6.  Mutations in RYR1 in malignant hyperthermia and central core disease.

Authors:  Rachel Robinson; Danielle Carpenter; Marie-Anne Shaw; Jane Halsall; Philip Hopkins
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

Review 7.  Genetics of malignant hyperthermia.

Authors:  Barbara W Brandom
Journal:  ScientificWorldJournal       Date:  2006-12-28

8.  Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse.

Authors:  Mihail G Chelu; Sanjeewa A Goonasekera; William J Durham; Wei Tang; John D Lueck; Joyce Riehl; Isaac N Pessah; Pumin Zhang; Meenakshi B Bhattacharjee; Robert T Dirksen; Susan L Hamilton
Journal:  FASEB J       Date:  2005-11-11       Impact factor: 5.191

9.  Genetic risk factors associated with lipid-lowering drug-induced myopathies.

Authors:  Georgirene D Vladutiu; Zachary Simmons; Paul J Isackson; Mark Tarnopolsky; Wendy L Peltier; Alexandru C Barboi; Naganand Sripathi; Robert L Wortmann; Paul S Phillips
Journal:  Muscle Nerve       Date:  2006-08       Impact factor: 3.217

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123
View more
  6 in total

1.  Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration.

Authors:  Cindy L Cain; Matthias L Riess; Lynn Gettrust; Jutta Novalija
Journal:  AORN J       Date:  2014-02       Impact factor: 0.676

2.  Life-threatening heat stroke presenting with ST elevations: a report of consecutive cases during the heat wave in Austria in July 2013.

Authors:  Elisabeth Lassnig; Patrick Dinkhauser; Edwin Maurer; Bernd Eber
Journal:  Wien Klin Wochenschr       Date:  2014-03-25       Impact factor: 1.704

3.  Anesthesia advanced circulatory life support.

Authors:  Vivek K Moitra; Andrea Gabrielli; Gerald A Maccioli; Michael F O'Connor
Journal:  Can J Anaesth       Date:  2012-04-21       Impact factor: 5.063

4.  The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.

Authors:  Caroline S Bennette; Carlos J Gallego; Wylie Burke; Gail P Jarvik; David L Veenstra
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

5.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16

6.  Nitric Oxide-induced Activation of the Type 1 Ryanodine Receptor Is Critical for Epileptic Seizure-induced Neuronal Cell Death.

Authors:  Yoshinori Mikami; Kazunori Kanemaru; Yohei Okubo; Takuya Nakaune; Junji Suzuki; Kazuki Shibata; Hiroki Sugiyama; Ryuta Koyama; Takashi Murayama; Akihiro Ito; Toshiko Yamazawa; Yuji Ikegaya; Takashi Sakurai; Nobuhito Saito; Sho Kakizawa; Masamitsu Iino
Journal:  EBioMedicine       Date:  2016-08-13       Impact factor: 8.143
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.